Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

February 13, 2025

M. Marin
mmarin@zacks.com
Ph (312) 265-9211

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

Aethlon Medical (AEMD-NASDAQ)

AEMD: *Patient Enrollments in Oncology Trial Expected to Accelerate With 3rd Participating Site, Protocol Amendments*

Our key takeaways from AEMD's business update yesterday include that the 1st patient treated in AEMD's trial of lead asset the Aethlon Hemopurifier®, which is being evaluated in combination with checkpoint inhibitors as a potential treatment for patients suffering from various solid tumor types, tolerated treatment with no adverse effects. With sites participating and following recent protocol amendments, AEMD expects patient enrollments and treatments to accelerate.

OUTLOOK

The company expects to conduct a capital raise that, along with the expected (and recent) exercise of outstanding warrants, could extend its cash runway significantly. Additionally, AEMD has made cost reductions and also stands to benefit from the up to 43.5% cash tax rebate on clinical trial-related R&D costs in Australia and lower costs of conducting clinical trials in India. Separately, while the company's near-term focus is on assessing the Hemopurifier as a potential treatment for oncology, longer-term AEMD continues to view the device as a potential tool in the treatment of viruses, organ transplants and other medical areas. The company will continue to monitor the situation with bird flu in case the need for treatment with the device arises.

Current Price (2/12/25)	$0.67
Valuation	**$0.75**

SUMMARY DATA

52-Week High	**$1.85**
52-Week Low	**$0.24**
One-Year Return (%)	**NA**
Beta	**1.75**
Average Daily Volume (sh)	**3,399,375**
Shares Outstanding (mil)	**14**
Market Capitalization ($mil)	**$9**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**11**
Insider Ownership (%)	**3**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2025 Estimate	**N/A**
P/E using 2026 Estimate	**N/A**

Risk Level	**High,**
Type of Stock	**Small-Blend**
Industry	**Med Products**

ZACKS ESTIMATES

Revenue
(in '000 of $)

	Q1 (Jun)	Q2 (Sep)	Q3 (Dec)	Q4 (Mar)	Year (Mar)
2022	0.1 A	0.1 A	0.0 A	0.0 A	0.3 A
2023	0.0 A	0.0 A	0.0 A	0.6 A	0.6 A
2024	0.0 A	0.0 A	0.0 A	0.0 A	0.0 A
2025	0.0 A	0.0 A	0.0 A	0.0 E	0.0 E

Earnings / loss per share

	Q1 (Jun)	Q2 (Sep)	Q3 (Dec)	Q4 (Mar)	Year (Mar)
2022	-$1.59 A	-$1.28 A	-$1.57 A	-$2.44 A	-$7.06 A
2023	-$1.88 A	-$1.84 A	-$1.24 A	-$1.07 A	-$5.86 A
2024	-$1.35 A	-$1.22 A	-$1.37 A	-$0.96 A	-$4.86 A
2025	-$0.34 A	-$0.20 A	-$0.13 A	-$0.13 E	-$0.72 E

Quarters might not add to annual reflecting rounding, share counts

Disclosures on page 10

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

POSITIVE TAKEAWAYS FROM COMPANY'S RECENT INITIATIVES

Patient treatments begin in AEMD's basket oncology trial, enrollments expected to accelerate

Aethlon Medical (NASDAQ: AEMD) reported FY 3Q results yesterday and provided a business update. We present our key takeaways in this note:

Key takeaways

- Lead asset the Aethlon Hemopurifier® is being evaluated in combination with checkpoint inhibitors as a potential treatment for patients suffering from various solid tumor types
- The 1st patient treated tolerated Hemopurifier treatment with no adverse effects
- With three Australian medical centers participating and following recent protocol amendments, AEMD expects patient enrollments and treatments to accelerate
- AEMD recently made some headcount reductions and other cost reductions and also stands to benefit from the up to 43.5% cash tax rebate on clinical trial-related R&D costs in Australia
- The company expects to conduct a capital raise that, along with the expected (and recent) exercise of outstanding warrants, could extend its cash runway significantly
- While the company's near-term focus is on assessing the Hemopurifier as a potential treatment for oncology, longer-term AEMD continues to view the device as a potential tool in the treatment of viruses, organ transplants and other medical areas

Aethlon has implemented initiatives to constrain costs. Operating expenses were roughly 50% lower in FY 3Q compared to the prior year 3Q ($1.8 million in 3Q FY25 versus $3.6 million), reflecting AEMD initiatives and the absence of 1-time expenses associated with the former CEO. Specifically, about $1.3 million of the decrease reflected lower payroll and related expenses. Of this, $900,000 was attributable to the separation expense AEMD recorded last year related to its Separation Agreement with its former CEO. Another roughly $400,000 reflected that the company has reduced headcount. Another roughly $300,000 of the OpEx decrease was related to lower professional fees, which the company expects to continue to contain.

The company's lead asset, the Aethlon Hemopurifier®, is being evaluated as a potential treatment for cancer and life threatening infectious diseases and for use in organ transplantation. The Hemopurifier is an extracorporeal device – in other words, it works outside the body, as illustrated in the figure below. The device is used on existing blood circulatory equipment such as dialysis and CRRT machines that are already installed in hospitals and clinics, making the Hemopurifier essentially a plug & play tool for medical centers.

The above-noted cost reductions were partially offset by a $200,000 cost increase related to clinical trials for the oncology clinical trials primarily in Australia, as well as in India. Costs related to clinical trials are likely to rise as the trials advance. However, the up to 43.5% cash tax rebate on clinical trial-related R&D costs in Australia are expected to optimize spending. The net loss was about $1.8 million, down from about $3.5 million in last year's 3Q.

The Hemopurifier has received FDA *Breakthrough Device* designation for two independent indications. The Hemopurifier has *Breakthrough Device* designation for the treatment of people with advanced or metastatic cancer who are either unresponsive to or cannot tolerate standard of care therapy, and with cancer types in which exosomes are indicated in the development or severity of the disease and also for life-threatening viruses that are not addressed with approved therapies.

First patient treated tolerated Hemopurifier treatment without complications

AEMD has made significant strides in moving its clinical activities forward over the past few months. In the near-term, AEMD's primary focus currently is on researching the Hemopurifier therapeutic blood filtration system as a potential treatment in oncology. The company enrolled the first three patients in its

oncology trial and treated the first. Last month Aethlon announced that the first patient in its Australian safety, feasibility and dose-finding clinical trial has been treated with the Hemopurifier. The first patient treated in the study was enrolled in the trial on October 29, 2024 at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia. After a two-month run in period of treatment with the anti-PD-1 drug Nivolumab during which serial measurements of EVs and anti-tumor T cell activity were taken, it was determined that the disease had progressed. The patient was then treated with the Hemopurifer on January 29, 2025.

Hemopurifier treatment was for four hours on a single day. The patient tolerated the procedure without complications. AEMD anticipates that data from the first treatment cohort will provide insight into the Hemopurifier's potential ability to reduce tumor-derived EVs and enhance T cell activity against tumors. Follow-up safety visits, EV and T cell measurements as well as imaging for clinical response, are planned as part of the clinical study.

Protocol amendments, participation of 3rd medical center in trial, expected to accelerate patient enrollments

Aethlon has implemented protocol amendments in the oncology study that include enrolling patients only after it has been confirmed that they are not to be responding to anti-PD-1 therapy. Two patients previously recruited were withdrawn from the study due to outcomes related to their anti-PD-1 therapies; this protocol adjustment eliminates the need to identify patients within the first 2 weeks of their beginning anti-PD-1 therapy and also removes the two-month run-in period that was required previously to assess response to therapy. In other words, it is expected to shorten the time required to enroll patients.

In addition, restrictions on commonly prescribed concomitant medications that do not impact patient safety have been lifted. The amended protocol also broadens eligibility to include patients receiving all approved dosing regimens of Pembrolizumab and Nivolumab, rather than limiting enrollment to specific schedules. As The company continues to pursue approval of a similar clinical trial in India, these protocol amendments inform the design of that trial, as well.

A third site that will participate in the study, the Genesis Care/ Royal North Shore Hospital, can begin enrollment under this amendment following a planned Site Initiation Visit (SIV) on February 14, 2025. The company believe this site has a sizable patient population undergoing treatment that might be eligible to participate in its study

As noted, AEMD expects to realize benefits from attractive economic incentives the Australian government provides for clinical development efforts and lower costs in India, where R&D expenses are substantially lower than in the U.S., according to management, and thereby maximize its R&D dollars. Australia offers an R&D tax incentives rebate program, which enables companies to receive a cash tax rebate of up to 43.5% on clinical trial related R&D costs and is expected to help it reduce costs, lower risk, and accelerate time to market.

Capital raise, warrant exercises could extend cash runway substantially

Aethlon had cash of about $4.8 million at the end of the December 2024 quarter to support its efforts. Moreover, Aethlon has a clean capital structure, with no debt and a single share class. The company has filed for a capital raise funds under a Reg A offering. If fully completed, this anticipated offering could give AEMD a long cash runway of up to an incremental roughly $20 million. At the same time, management expects the potential exercise of warrants to also add to its cash position. In fact, subsequent to the close of the December 31, 2024 quarter, in January and February 2025, holders of Class A warrants and Class B warrants exercised warrants.

Company optimistic that patient enrollments or AEMD's basket oncology trial will accelerate

AEMD's study is a basket oncology trial to study the impact of the Hemopurifier in patients with various solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment. It is a phase 1 safety, feasibility and dose-finding study. With a basket trial, the company will administer Hemopurifier treatment to patients suffering from various solid tumor types. Checkpoint inhibitors are also used to treat a broad range of tumor types. In fact, checkpoint inhibitors such as Keytruda® have been used to treat 25+ different types of cancer. If the study shows the Hemopurifier to be beneficial in multiple cancer types, the company believes the data will support the broad utility of the device. Moreover, by focusing on multiple cancers and including patients with a variety of solid tumors, the company has also expanded the opportunities for patient enrollment and can build a database to support regulatory approval. Including both Keytruda and Opdivo® is also expected to facilitate patient enrollments. The goal is to build its database in oncology to help with the development of the Hemopurifier as an oncology treatment.

The clinical activities are being conducted in Australia and India, which has multiple advantages. Clinical development costs generally are lower in both markets. In addition, assessing participants in both markets will also enable the company to determine the Hemopurifier impact on diverse patient populations. Each patient will be its own control, as a patient's EV level pre- and post Hemopurifier treatment will be monitored. If there is a quantifiable decrease in EV levels, the Hemopurifier treatment is expected to improve their T-cell's ability to fight the cancer.



Source: Aethlon Medical

Primary endpoint safety; trial will also assess safety, feasibility, dose-finding

The primary endpoint of the roughly 9-to-18 patient, safety, feasibility and dose-finding trial is **safety**. The trial will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals following two months of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the PD-1 therapy will be eligible to participate in AEMD's Hemopurifier study.

We would expect AEMD to announce the data from the first cohort of patients once all three patients have been treated. The company's trial will analyze whether the Hemopurifier can help decrease the concentration of EVs in cancer patients and thereby improve overall patient outcomes, as noted. The

company's objective in designing the trial was to test the Hemopurifier in a patient population that is already receiving checkpoint inhibitor treatment but could obtain incremental benefit from the Hemopurifier. The company's hypothesis is that using the Hemopurifier in conjunction with treatment of checkpoint inhibitors can increase the percent of patients who can benefit from combined treatment. The company expects the Hemopurifier, in conjunction with an inhibitor, can help improve overall patient outcomes and demonstrate proof of concept about the device's benefits in treating solid tumors. The company is optimistic that the trial will show the Hemopurifier's ability in conjunction with Optivo or Keytruda that block anti-PD1 to improve body's cancer fighting ability.

In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. Participating patients will be assigned to one of three different cohorts: cohort 1 will receive one Hemopurifier treatment during a one-week period, cohort 2 will receive two treatments and cohort 3 will receive three treatments during a one-week period. Analysis of the data generated from this study will be used to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study to move toward regulatory approval. Following completion of treatment, the company will continue to follow patient participants.

Oncology market unfortunately is large

If Aethlon can demonstrate the ability of the Hemopurifier to improve outcomes of cancer patients suffering from a variety of different cancer types, we would anticipate strong commercial prospects for the Hemopurifier. AEMD believes it can generate data to support the Hemopurifier's ability when combined with checkpoint inhibitor treatment to improve outcomes in multiple tumor types where cancer associated extracellular vesicles, or EVs, may promote immune suppression and resistance to anti-PD-1 antibodies. The Hemopurifier has demonstrated the ability to remove exosomes; management believes the device can be used to affect improved outcomes in a number of cancers.

Unfortunately, the oncology population is large. Some 40% of all cancer patients are eligible for checkpoint inhibitor treatment, according to AEMD, with about two million patients treated annually with Keytruda and an additional patient population with Optivo. However, as noted, currently, only about 30% of cancer patients who receive these treatments for solid tumors have lasting clinical responses. If the Hemopurifier, in conjunction with these treatments, can improve outcomes for a higher percentage of patients, the benefits would be substantial, in our view, as would the expected commercial prospects of the Hemopurifier.

The company has indicated that while a few smaller public companies are also developing extracorporeal medical devices, but none are conducting clinical activities in the oncology space. One privately-held company apparently might be entering the oncology space, but the mechanism of action of its device is different from that of the Hemopurifier, according to management.


Longer-term Hemopurifier could serve as treatment for a range of indications

Longer-term, the company believes its proprietary GNA affinity resin creates a competitive edge that could make the device beneficial for treatment of a range of indications. The Hemopurifier has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids utilizing its proprietary lectin-based technology. This action has potential applications in the area of oncology, where exosomes and exosomal particles are thought to promote immune suppression and metastasis, and in life-threatening infectious diseases.

The company has completed substantial preclinical, in vitro and in human analysis of the Hemopurifier. These activities have demonstrated virus and EV (which include exosomes) clearance both in vitro and in patients. In humans, the Hemopurifier has been administered safely and was well tolerated in 38 patients in an aggregate 164 sessions. The company also recently completed an *in vitro* binding study of relevant oncology targets, to provide pre-clinical evidence to support the upcoming trial design.

AEMD's *in vitro* binding study indicated positive results supporting that the Hemopurifier removes EVs from plasma and provides pre-clinical evidence to support the planned phase 1 safety, feasibility and dose-finding clinical trials in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. EVs are released from the parent cell and tumor cells generally have more mannose compared to healthy cells. EVs have been shown to contribute to metasisis of the malignancy and to suppressing the body's immune system from helping the body fight disease. If the Hemopurifier can remove a quantifiable amount of EVs, it is expected it can help improve responses to standard-of-care cancer therapy.

Pipeline Targeting Multiple Indications



Source: Company presentation

VALUATION

We believe the potential utility of the Hemopurifier could be in a broad range of oncology and other treatments. As the company continues to advance the Hemopurifier through clinical efforts towards regulatory approval and hit certain milestones, in turn likely leading to greater awareness and investor interest in the company, we would anticipate multiple expansion on AEMD shares.

As noted, the cancer treatment market unfortunately is large and growing and if clinical testing of the Hemopurifier supports its potential role as an oncology treatment, we would anticipate significant commercial potential. For instance, sales of Keytruda exceeded $20 billion in 2022, according to Merck.

If Aethlon's planned initial oncology trials warrant continuing to advance the Hemopurifier for treatment in this area, as management expects, we believe it would not be unreasonable to expect that the company could reach the $90 million revenue range by the 2028-2030 timeframe. Discounting back at about 12%-13% per annum. We are lowering our confidence factor regarding timing to 20% to 25% from 25% to 30% before. Applying this new range leads to a current valuation of about $0.75 per share. Our confidence factor largely reflects the potential timeline. As noted, given the lack of truly effective cancer therapies, we think that there is reason to believe that a cancer indication for the Hemopurifier is an eventual realistic outcome. Clinical evidence supports the role of exosomes in the progression of cancer and, similarly, that removing tumor-derived exosomes from circulation might inhibit tumor growth and/or potentially improve the effectiveness of immunotherapies. As Aethlon pursues studies of the Hemopurifier in a potential cancer indication, we think a growing database of evidence could have important consequences, including potentially influencing key opinion leaders and regulators alike.

We reiterate that our valuation is based on the company's current preliminary development state. It does not incorporate potential from treatment of viruses or in organ transplant or other applications. Moreover, AEMD shares have come under pressure reflecting, we believe, general market and economic uncertainty and the rising interest

rate environment. We believe uncertainty could continue to overhang the shares in the near-term, similar to many other early stage pre-revenue life sciences companies, particularly as it is difficult to know the company's revenue arc at this early stage in the development of the Hemopurifier.

While we believe there could be a meaningful revenue opportunity associated with the Hemopurifier within the oncology space, depending on the potential benefits of the Hemopurifier in multiple types of cancers, we do not expect the shares to begin to reflect this at this early stage and, as noted, we believe uncertainty around the company's clinical / commercialization timeline and market / economic uncertainty could continue to overhang the shares in the near-term.

RECENT NEWS

- Aethlon announced FY 3Q results and provided a business update on February 12, 2025.
- On Jan 29, 2025, AEMD treated the first patient in its Hemopurifier® cancer trial in Australia.
- On November 11, 2024, AEMD enrolled the first patient in (FPI) in its Hemopurifier® cancer trial in Australia.
- AEMD received Ethics Committee approval in India for the Hemopurifier® trial on September 19, 2024.
- Aethlon received approval from the Bellberry Human Research Ethics Committee on August 12, 2024.
- On June 18, 2024, Aethlon received Ethics Committee approval from Central Adelaide Local Health Network.
- AEMD reported positive in vitro data on May 10, 2024.
- On February 21, 2024, Aethlon Entered into a materials transfer agreement for Santersus AG's NucleoCapture and HemoNucleoCapture devices.
- AEMD announced 3Q FY24 results on February 14, 2024.
- On November 13, 2023, the company announced that it had named James Frakes as interim CEO.

RISKS

Risks to Aethlon achieving its objectives, and to our valuation, include the following.

- AEMD might need to raise additional capital earlier than or at rates that are more dilutive than expected.
- There might be delays in the company's clinical and subsequent commercialization timelines.
- The clinical trials might not produce the results that management anticipates.
- Despite receiving two FDA Breakthrough Device designations, the FDA approval might take longer than expected or might not come at all.
- The company might not be able to advance the Hemopurifier in various programs.


Aethlon Medical Inc.

AEMD ($000s)	2023 A	1Q24 A	2Q24 A	3Q24 A	4Q24 A	2024 A	1Q25 A	2Q25 A	3Q25 A	4Q25 E	2025 E
Year ends March 31											
ue	$574.2	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
YOY Growth	*95.2%*					*NM*					*NM*
Cost of Goods Sold	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Income	$574.2	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Gross Margin	*NM*					*NM*					*NM*
OpEx	$9,727.9	$2,729.2	$2,546.9	$2,973.7	$1,866.7	$10,116.6	$2,206.2	$2,640.6	$1,574.5	$1,576.1	$7,997.5
SG&A % of Prod Sales	*NM*	*NM*	*NM*	*NM*	*NM*	*NM*					*NM*
R&D	$2,745.0	$678.9	$628.4	$593.4	$619.2	$2,520.0	$414.7	$261.5	$240.2	$257.0	$1,173.4
R&D % Tot Sales											
ting Income	($11,898.6)	($3,408.2)	($3,175.3)	($3,567.1)	($2,486.0)	($12,636.6)	($2,620.9)	($2,902.1)	($1,814.7)	($1,833.1)	($9,170.9)
Operating Margin											
Total Other Expense	$131.1	($125.0)	($140.9)	($101.0)	($61.6)	($428.4)	($49.4)	($95.1)	($60.0)	($59.4)	($263.9)
ax Income	($12,029.8)	($3,283.2)	($3,034.5)	($3,466.1)	($2,424.4)	($12,208.2)	($2,571.4)	($2,807.0)	($1,754.8)	($1,773.8)	($8,907.0)
Other comprehensive inc				$8.0	($8.8)	($0.8)		$3.8	($13.1)		($9.3)
Taxes (benefit)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Tax Rate	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*
Minority interest	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
come	($12,029.8)	($3,283.2)	($3,034.5)	($3,458.2)	($2,424.4)	($12,209.0)	($2,571.4)	($2,803.2)	($1,767.8)	($1,773.8)	($8,916.2)
Net Margin											
	($5.86)	($1.35)	($1.22)	($1.37)	($0.96)	($4.86)	($0.34)	($0.20)	($0.13)	($0.13)	($0.72)
Diluted Shares O/S	2,054	2,431	2,484	2,517	2,515	2,513	7,458	13,938	13,962	13,972	12,333

Source: Zacks *Pro forma for reverse stock split*

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

HISTORICAL STOCK PRICE



© Copyright 2025, Zacks Investment Research. All Rights Reserved.

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, M. Marin, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.